Management of Mineralocorticoid Receptor Antagonists
Introduction to Mineralocorticoid Receptor Antagonists
- Mineralocorticoid receptor antagonists, such as eplerenone and spironolactone, are used to treat heart failure and other conditions, with guidelines supported by the American Heart Association, American College of Cardiology, and Heart Failure Society of America 1, 2
Dosing Considerations
- The American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend avoiding mineralocorticoid receptor antagonists like eplerenone when eGFR is <30 mL/min/1.73 m² due to increased risk of hyperkalemia and worsening renal function 1, 2
- Eplerenone can be restarted at a reduced dose after confirming resolution of hyperkalemia/renal insufficiency for at least 72 hours, as suggested by guidelines from Circulation 3
- The following dosing guidelines are recommended for spironolactone:
| eGFR (mL/min/1.73 m²) | Initial Dose | Maintenance Dose |
|---|---|---|
| ≥50 | 25 mg once daily | up to 50 mg once daily |
| 30-49 | 25 mg every other day | 25 mg once daily |
| <30 | Avoid use | - |
- The following dosing guidelines are recommended for eplerenone:
| eGFR (mL/min/1.73 m²) | Initial Dose | Maintenance Dose |
|---|---|---|
| ≥50 | 25 mg once daily | up to 50 mg once daily |
| 30-49 | 12.5-25 mg once daily or 25 mg every other day | 12.5-25 mg once daily |
| <30 | Avoid use | - |
- Eplerenone is an alternative for patients who develop gynecomastia on spironolactone, starting at 25 mg daily and titrating to 50 mg daily, as recommended by the European Society of Cardiology 4
Concomitant Medications and Interactions
- The American Heart Association recommends that ACE inhibitors or ARBs be used with caution when taking spironolactone, as they significantly increase the risk of hyperkalemia 5, 6, 3
- Concomitant use of NSAIDs and COX-2 inhibitors with spironolactone should be done with caution, as they can lead to worsening renal function and hyperkalemia 5, 6, 3
- Potassium supplements should generally be discontinued when starting spironolactone to minimize the risk of hyperkalemia 5
- Spironolactone is typically used in combination with loop diuretics for enhanced diuretic effect, as recommended by the American Heart Association 7
Monitoring and Follow-up
- The American Heart Association recommends checking potassium and renal function within 3 days of spironolactone initiation, and rechecking at 1 week, with monthly monitoring for the first 3 months 5
- The American Heart Association also recommends monitoring every 3 months thereafter if the patient is stable 5
- The European Heart Association recommends checking serum potassium and renal function 5-7 days after initiation of spironolactone, and rechecking every 5-7 days until values are stable, then monitoring every 3-6 months 8
- Patients on spironolactone require regular monitoring of serum potassium and renal function, with recommended checks at baseline, 1 week, 1 month, and then at 1, 2, 3, and 6 months after initiation, followed by monitoring every 6 months if stable, as recommended by the American College of Cardiology 4
- Medications should be held if potassium rises to >5.5 mmol/L or if creatinine rises to >220 μmol/L (2.5 mg/dL), and stopped immediately if potassium >6.0 mmol/L or creatinine >310 μmol/L (3.5 mg/dL), as recommended by the European Society of Cardiology 9
Discontinuation and Special Considerations
- Abrupt discontinuation of spironolactone in patients with heart failure and chronic kidney disease is not recommended due to potential worsening of heart failure symptoms and increased mortality risk, as warned by the American College of Cardiology 10
- Before discontinuing spironolactone, evaluate current renal function, including serum creatinine levels, with concern if >2.5 mg/dL or >221 μmol/L, and monitor closely for signs of worsening heart failure, as recommended by the European Society of Cardiology 10
- Schedule follow-up within 2-4 weeks to assess heart failure status after discontinuation, as suggested by the American Heart Association 10
- The American Academy of Dermatology recommends that patients avoid high-potassium foods during spironolactone treatment to minimize the risk of hyperkalemia 11
Clinical Outcomes and Benefits
- Spironolactone reduces mortality by 30% in patients with severe heart failure (NYHA class III-IV) and decreases hospitalizations for worsening heart failure by 35%, as supported by the European Society of Cardiology 4
- Specific treatments, such as beta blockers and spironolactone, may reduce sudden cardiac death by 30-54% in heart failure patients, and improve diastolic function, with a guideline strength based on evidence from 2022 12, 1